Cash is actually a bit higher than that at ~$200 Million (and growing all the time). Any other Biotech is forward looking with Revenues and (hopefully) profits, here the most proven and continually efficient profit generating small Biotech business is not priced for any future growth at all despite a blockbuster phase 3 looking very good and not far off with a drug that already has the big FDA tick of approval. This makes it especially weird with the lack of buyback, they have continually repeated that $20 Million figure for a buyback so here they could actually complete the buyback for just $15 Million which is well under that stated $20 Mill figure. Everlasting benefits to EPS etc and at the very least just honouring their own words.
All IMO DYOR
CUV Price at posting:
$9.90 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)